Polyrizon (PLRZ) Stock Price

Polyrizon Price

CLOSED
9.61
​
Market closed

Polyrizon stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Polyrizon business model & stock analysis

Polyrizon Ltd develops medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity to block viruses and allergens. The company specializes in creating a biological mask using naturally occurring building blocks, focusing on both product development and commercialization. Medical specialists and researchers collaborate with Polyrizon Ltd to advance their intranasal solutions. The firm's primary revenue comes from the development and commercialization of its nasal spray hydrogel products. These products target healthcare providers and consumers seeking protection against viral and allergen exposure. By forming a shield containment barrier, Polyrizon Ltd offers a solution that complements existing health measures without requiring additional equipment. Polyrizon Ltd's business model centers on the creation of a unique nasal barrier technology. The company leverages its focus on intranasal delivery to address market needs for non-invasive protection. Its collaboration with medical specialists ensures that its products meet clinical standards and user requirements.

Frequently asked questions about Polyrizon

Converted at the current exchange rate, the Polyrizon share trades at 8.56 EUR (9.61 USD).

The revenue cannot currently be calculated for Polyrizon.

The profit cannot currently be calculated for Polyrizon.

The P/E ratio cannot be calculated for Polyrizon at the moment.

The P/S cannot be calculated for Polyrizon currently.

The Eulerpool Quality Score for Polyrizon is 2/10.

The ISIN of Polyrizon is IL0011814113. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Polyrizon is PLRZ. The ticker symbol is used to trade Polyrizon shares on the stock exchange.

Fair ValueTerminal
8.84 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Country
Israel
Currency
USD
Initial public offering
Oct 29, 2024
ISIN
IL0011814113
Cusip
M79549107
Market capitalization
6.54 M USDMicro Cap
52-Week Range
PEG
—
P/E ratio
P/Ee
—
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
0.31
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-15.89 %
Last updated Oct 21, 2026, 8:33 PM

Polyrizon Peer Group

All fundamentals and in-depth analysis of Polyrizon

Our stock analysis for Polyrizon stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Polyrizon. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.